▎ 摘　　要

NOVELTY - Method for identifying biomarkers from two or more distinct biomolecule classes in a biofluid involves (a) contacting several nanoparticles with a biofluid to allow a biomolecule corona to form on surface of nanoparticles, (b) isolating the nanoparticles and surface-bound biomolecule corona, and (c) analyzing the biomolecule corona to identify biomarkers from two or more distinct biomarker classes. USE - The method is useful for identifying biomarkers from two or more distinct biomolecule classes in a biofluid, detecting a disease state and monitoring cancer progression in subject. The biomarker classes are at least one chosen from protein, nucleic acid (DNA or RNA) and lipid or their complexes. The nucleic acid is cfDNA. The cfDNA is genomic DNA. The cancer is chosen from ovarian, lung, prostate, melanoma and blood cancer, preferably leukemia, lymphoma and myeloma (all claimed). ADVANTAGE - The method identifies biomarkers from two or more distinct biomolecule classes in biofluid, and monitors cancer progression in an accurate and cost-effective manner with increased sensitivity and specificity. The method detects disease state at an early stage. DETAILED DESCRIPTION - INDEPENDENT CLAIMS are included for the following: (1) method for detecting a disease state in a subject involves (a) contacting a biofluid sample from the subject with several nanoparticles under conditions to allow a biomolecule corona to form on the surface of nanoparticles, and (b) analyzing the biomolecule corona for one or more disease-specific biomarkers from two or more biomolecule classes, which is determinative of presence of a disease in subject; and (2) method for monitoring cancer progression in a subject involves (a) contacting a biofluid sample from the subject with nanoparticles under conditions to allow a biomolecule corona to form on the surface of nanoparticles, and (b) analyzing the biomolecule corona for one or more cancer-specific biomarkers from two or more biomolecule classes, where the degree of cancer progression is determined based on level of cancer-specific biomarker(s) relative to a reference amount.